Plus Therapeutics
PSTV
10 hedge funds and large institutions have $118K invested in Plus Therapeutics in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 0 closing their positions.
67% more funds holding
Funds holding: 6 → 10 (+4)
0.04% less ownership
Funds ownership: 0.16% → 0.12% (-0.04%)
43% less capital invested
Capital invested by funds: $205K → $118K (-$87.6K)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$42.4K |
| 2 |
HF
HRT Financial
New York
|
+$24.1K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$20.5K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$11.1K |
| 5 |
Citigroup
New York
|
+$1.24K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$122K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$7.03K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Geode Capital Management
Boston,
Massachusetts
| $35.6K | +$20.5K | +382 | +56% |
|
|
2
Millennium Management
New York
| $26.5K | +$42.4K | +790 | New |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $21.7K | -$122K | -2,266 | -78% |
|
|
HF
4
HRT Financial
New York
| $15K | +$24.1K | +449 | New |
|
5
BlackRock
New York
| $9.33K | – | – | – |
|
|
6
UBS Group
Zurich,
Switzerland
| $6.9K | +$11.1K | +206 | New |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| $1.94K | -$7.03K | -131 | -69% |
|
|
8
Citigroup
New York
| $776 | +$1.24K | +23 | New |
|
9
Osaic Holdings
Scottsdale,
Arizona
| $178 | – | – | – |
|
10
Wells Fargo
San Francisco,
California
| $28 | – | – | – |
|
11
JP Morgan Chase
New York
| $3 | – | – | – |
|
12
Group One Trading
Chicago,
Illinois
| $1 | – | – | – |
|
PSTV Hedge Fund Activity: Q3 2023 in Review
10 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Plus Therapeutics (PSTV) for Q3 2023, worth a combined $118K — down 43% from $205K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new PSTV positions and 0 closed out — a net gain of 4 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $42.4K. The largest seller was Vanguard Group, cutting an estimated $122K.
- 10 institutional investors held Plus Therapeutics (PSTV) as of Q3 2023, up from 6 in Q2 2023.
- Funds reported $118K of Plus Therapeutics stock for Q3 2023, down 43% quarter-over-quarter.
- 4 funds opened new Plus Therapeutics positions in Q3 2023 and 0 closed out, a net change of +4 holders.
- The largest Plus Therapeutics buyer in Q3 2023 was Millennium Management, an estimated $42.4K added.
- The largest Plus Therapeutics seller in Q3 2023 was Vanguard Group, an estimated $122K sold.
Based on aggregated 13F filings for Q3 2023.